SEPN · CIK 0001984086
What Septerna, Inc. told the SEC could break it.
Septerna's disclosures are those of an early-stage biotech with no product revenue yet — a $48.9M FY2025 net loss and a $167.3M accumulated deficit, cushioned by roughly $548.7M of cash — whose path to market runs through manufacturing it doesn't own. It depends on a limited set of drug-substance makers, some sole-source, where switching suppliers may not be feasible on reasonable terms, and on service arrangements with China-based WuXi that leave it exposed to tariffs and export controls on the raw materials and candidates it imports. Should its candidates reach approval, pricing would further face IRA reforms and proposed most-favored-nation models like GLOBE.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- tariffs/export controls on China imports (WuXi service arrangements)medium
Tariffs and export controls could raise the cost of manufacturing candidates and platform materials and disrupt import/export of raw materials and finished candidates from China under Septerna's WuXi service arrangements.
“iffs, may increase the cost of manufacturing our product candidates and platform materials, affect our ability to commercialize our product candidates if approved, the competitive position of our product candidates, and import or export of raw materials and finished product candidate used in our preclinical studies and clinical trials, particularly with respect to any product candidates and materials that we import from China, including pursuant to our service arrangements with WuXi.”
- drug-pricing reform (IRA, MFN GLOBE/GUARD, EU price controls)medium
IRA provisions, proposed MFN pricing models (GLOBE/GUARD) for single-source/sole-source Medicare drugs, and EU/Canada price controls could pressure future pricing of Septerna's candidates if approved.
“the Global Benchmark for Efficient Drug Pricing Model (“GLOBE”) for Medicare Part B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS's spending and eligibility criteria.”
SEC filing →As of 2026
Other disclosures
- preclinical/clinical-stage; no product revenue; $167.3M deficitmedium
Septerna's product candidates are in preclinical/early-clinical development; it has generated no product revenue, posted a $48.9M FY2025 net loss and a $167.3M accumulated deficit (offset by ~$548.7M cash).
“For the year ended December 31, 2025 , the Company incurred net loss of $ 48.9 million . The Company had an accumulated deficit of $ 167.3 million as of December 31, 2025.”
SEC filing →As of 2026
Supplier concentration
- limited/sole-source drug-substance manufacturersmedium
Drug substances for Septerna's candidates come from a limited number of manufacturers (some sole-source); switching to an alternative supplier might not be possible on commercially reasonable terms and would take significant time/expense.
“While the drug substances used in our product candidates are manufactured by more than one supplier, the number of manufacturers is limited. In the event it is necessary or advisable to acquire supplies from an alternative supplier, we might not be able to obtain them on commercially reasonable terms, if at all.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Vertex Pharmaceuticals Incorporated
“Collaboration Agreement, we received a one-time, non-refundable upfront payment of $195.0 million. In August 2025, we received a $12.5 million milestone payment from the Vertex Asset Purchase Agreement.”
Cited →
Its suppliers
WuXi (China CRO/CMO)
“import or export of raw materials and finished product candidate used in our preclinical studies and clinical trials, particularly with respect to any product candidates and materials that we import from China, including pursuant to our service arrangements with WuXi.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch